SCHEMBL21267964

SCHEMBL21267964

O=COCC1CCCCN1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 8/20 0.41
FDPS P14324 2/20 0.41
CYP2D6 P10635 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
MLNR O43193 1/20 0.40
ABCB11 O95342 1/20 0.40
EGFR P00533 1/20 0.40
FYN P06241 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
HTR1A P08908 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23418534 1.00 LTA4H (0.41) LTA4HFDPSCYP2D6MEN1LMNA
Hydrochloric Acid SCHEMBL28272703 0.98 LTA4H (0.41) LTA4HFDPSCYP2D6MEN1LMNA
SCHEMBL28254273 0.98 CYP2D6 (0.43) LTA4HFDPSCYP2D6MEN1LMNA
SCHEMBL5021487 0.94
SCHEMBL27521887 0.94
Hydrochloric Acid SCHEMBL27806461 0.92 CHRNA3 (0.40) LTA4H
Acrylic Acid SCHEMBL28267416 0.87 MEN1 (0.44) LTA4HFDPSCYP2D6MEN1LMNA
SCHEMBL28011980 0.83
Hydrochloric Acid SCHEMBL28577065 0.81
SCHEMBL27554819 0.81 KMT2A (0.39) LTA4HFDPSCYP2D6MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114426514-B Large-scale synthesis method of natural alpha-glucosidase inhibitor Penosulfate A 江汉大学 2023-10-24 CN claimed
CN-114426514-A Large-scale synthesis method of natural alpha-glucosidase inhibitor Penasulfate A 江汉大学 2022-05-03 CN claimed
CN-109232388-B Synthetic method of natural alpha-glucosidase inhibitor Penasulfate A 江汉大学 2021-11-16 CN claimed
CN-109232388-A A kind of synthetic method of natural ɑ-glucosidase inhibitor Penasulfate A 江汉大学 2019-01-18 CN claimed
CN-107827887-B Triazole methyl esters link volution compound with antibacterial activity and its preparation method and application 上海博栋化学科技有限公司 2019-01-08 CN claimed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
CN-114426514-B Large-scale synthesis method of natural alpha-glucosidase inhibitor Penosulfate A 江汉大学 2023-10-24 CN disclosed
US-20220402841-A1 Stilbene Derivative and Method for Preparing Same Ozchela Inc. (KR) 2022-12-22 US disclosed
CN-114426514-A Large-scale synthesis method of natural alpha-glucosidase inhibitor Penasulfate A 江汉大学 2022-05-03 CN disclosed
CN-110092753-B Preparation method for synthesizing 3-azabicyclo [4.1.0] heptane-2-formic acid and hydrochloride thereof 南京药石科技股份有限公司 2022-04-26 CN disclosed
CN-109232388-B Synthetic method of natural alpha-glucosidase inhibitor Penasulfate A 江汉大学 2021-11-16 CN disclosed
US-20190255009-A1 STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME OZCHELA INC (KR) 2019-08-22 US disclosed
CN-109232388-A A kind of synthetic method of natural ɑ-glucosidase inhibitor Penasulfate A 江汉大学 2019-01-18 CN disclosed
CN-108912111-A compounds and pharmaceutical compositions 铁木医药有限公司 2018-11-30 CN disclosed
CN-105408328-B sGC stimulators 铁木医药有限公司 2018-11-16 CN disclosed
CN-108699001-A HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS 因赛特公司 2018-10-23 CN disclosed
CN-108368090-A Compounds as Immunomodulators 百时美施贵宝公司 2018-08-03 CN disclosed
CN-106459032-A Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection 豪夫迈·罗氏有限公司 2017-02-22 CN disclosed
CN-105517574-A Combinations of hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2016-04-20 CN disclosed
CN-104302290-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2015-01-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190255009-A1 STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME HPN, P4HB, FKBP1B LTA4H 1104/4885FDPS 132/4885CYP2D6 494/4885
US-20220402841-A1 Stilbene Derivative and Method for Preparing Same FKBP1B, FKBP8, FKBP2 LTA4H 1430/4885FDPS 48/4885CYP2D6 2314/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS LTA4H 2388/4885FDPS 2178/4885CYP2D6 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.